Paratek Pharmaceuticals Announces Stockholder Approval Of Acquisition By Gurnet Point Capital And Novo Holdings A/S

9/18/23 9:39:01 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $PRTK alert in real time by email

Paratek Pharmaceuticals, Inc. ("Paratek") (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today announced, based on a preliminary vote count, that stockholders have approved the merger agreement proposal at Paratek's special meeting of stockholders, in connection with the previously announced definitive agreement to be acquired by Gurnet Point Capital ("Gurnet Point") and Novo Holdings A/S ("Novo Holdings").

Final voting results for the special meeting will be disclosed on Form 8-K filed by Paratek with the U.S. Securities and Exchange Commission.

Get the next $PRTK alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PRTK

Date	Price Target	Rating	Analyst
5/2/2023	$7.00 → $5.00	Buy	Jefferies
4/17/2023	$24.00	Buy	BTIG Research
2/10/2022	$11.00	Buy → Strong Buy	WBB Securities
11/9/2021	$28.00 → $27.00	Buy	HC Wainwright & Co.

More analyst ratings

$PRTK
Leadership Updates

Live Leadership Updates

Paratek Pharmaceuticals Appoints Jeffrey Stein as Lead Independent Director of the Board
BOSTON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the Company's independent directors of the Board have appointed Jeffrey Stein, PhD as its first Lead Independent Director, effective December 8, 2022. Dr. Stein was selected unanimously by the independent directors of the Board, in recognition of his extensive leadership experience, in-depth knowledge of Paratek and the business of the anti-infective industry, strong financial and operational track record, and demonstrated independent judgment, integrity and commitment to the role. Having served as a director of Paratek since its emergence as a public company in 2014, Dr. Stein
12/20/22 7:30:00 AM ET
$PRTK
Biotechnology: Pharmaceutical Preparations
Health Care
Lantheus Announces Appointment of Minnie Baylor-Henry as New Board Member
NORTH BILLERICA, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("the Company") (NASDAQ:LNTH), today announced the appointment of Ms. Minnie Baylor-Henry, Esq., a renowned expert in regulatory affairs and compliance in the life sciences industry, to Lantheus' Board of Directors ("Board"), effective immediately. As an independent director, Ms. Baylor-Henry will serve as a member of the Board's Compensation Committee and the Science and Technology Committee. Following the appointment of Ms. Baylor-Henry, the Board will be comprised of nine directors, eight of whom are independent. "We are pleased to welcome Minnie Baylor-Henry, a highly respected authority in FDA law an
3/1/22 4:05:00 PM ET
$APYX
$LNTH
$PRTK
$SCPH
Medical/Dental Instruments
Health Care
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Adaptive Phage Therapeutics Expands Board Following Series B Financing Led by Deerfield Management
- Evan Loh, M.D., Jonathan Leff, and Jana Jensen, Ph.D., Appointed Directors of APT - Adaptive Phage Therapeutics, Inc. ("APT"), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced the appointment of Evan Loh, M.D., CEO of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), Jonathan Leff, Partner at Deerfield Management, and Jana Jensen, Ph.D., Chief Operating Officer at Deerfield Discovery and Development, to the company's Board of Directors. "We are delighted to welcome Evan, Jonathan, and Jana to APT's Board, as we expand our team following the successful completion of our $40.75 million Series B financing," said Greg Merril, A
6/29/21 8:00:00 AM ET
$PRTK
Biotechnology: Pharmaceutical Preparations
Health Care

$PRTK
Press Releases

Fastest customizable press release news feed in the world

Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Gurnet Point Capital ("Gurnet Point") and Novo Holdings A/S ("Novo Holdings") announced today the completion of their acquisition of Paratek Pharmaceuticals, Inc. ("Paratek" or the "Company") (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats. The Company's lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structu
9/21/23 8:58:57 AM ET
$PRTK
Biotechnology: Pharmaceutical Preparations
Health Care
Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/S
BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today announced, based on a preliminary vote count, that stockholders have approved the merger agreement proposal at Paratek's special meeting of stockholders, in connection with the previously announced definitive agreement to be acquired by Gurnet Point Capital ("Gurnet Point") and Novo Holdings A/S ("Novo Holdings"). Final voting results for the special meeting will be disclosed on Form 8-K filed by Paratek with th
9/18/23 9:37:40 AM ET
$PRTK
Biotechnology: Pharmaceutical Preparations
Health Care
Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/S
BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today announced that a second leading independent proxy advisor Glass, Lewis & Co. ("Glass Lewis") has recommended that stockholders vote FOR the Company's previously announced definitive agreement to be acquired by Gurnet Point Capital ("Gurnet Point") and Novo Holdings A/S ("Novo Holdings"). The Glass Lewis recommendation follows the recent receipt of the recommendation from Institutional Shareholder Services Inc. (
9/12/23 7:30:00 AM ET
$PRTK
Biotechnology: Pharmaceutical Preparations
Health Care

$PRTK
Financials

Live finance-specific insights

Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 Million
-- NUZYRA® (omadacycline) Net U.S. Sales of $33.8 Million from the Core Commercial Business, a 35% Increase Over Second Quarter 2022 --Previously Announced Agreement to be Acquired by Gurnet Point Capital and Novo Holdings A/S; Transaction Expected to Close in the Third Quarter BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), ("Paratek" or "the Company"), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today reported financial results and provided an update on corpora
8/3/23 8:00:00 AM ET
$PRTK
Biotechnology: Pharmaceutical Preparations
Health Care
Paratek Pharmaceuticals Announces First Quarter 2023 Revenue of $31.2 Million
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $26.2 Million from the Core Commercial Business, a 32% Increase Over First Quarter 2022 -- Company Reiterates Full-Year Revenue Guidance of $143 to $158 Million -- Announces Full-Year R&D and SG&A Expense Guidance of $160 to $170 Million, Approximately $20 Million in Savings Over Annualized Fourth Quarter 2022 Spend Rate1, Enabled by Operational Efficiencies BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats fo
5/9/23 4:05:00 PM ET
$PRTK
Biotechnology: Pharmaceutical Preparations
Health Care
Paratek Pharmaceuticals to Report Financial Results for First Quarter 2023 on May 9
BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the company will host a conference call and live audio webcast on Tuesday, May 9 at 4:30 p.m. EDT to report financial results for first quarter 2023.The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPharma.com.Domestic investors wishing to participate in the call will dial: 800-920-3371 and international investors will dial: +1-212-231-2909. The conference ID is 22026760. Investors can also access the call at: https://viavid.webcasts.com/starthere.jsp?ei=1611304&tp_key=5fe62a51b9About Paratek Phar
5/1/23 8:30:00 AM ET
$PRTK
Biotechnology: Pharmaceutical Preparations
Health Care

Paratek Pharmaceuticals Announces Stockholder Approval Of Acquisition By Gurnet Point Capital And Novo Holdings A/S

Chat with this insight

Recent Analyst Ratings for $PRTK

$PRTK Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Paratek Pharmaceuticals Inc.

SEC Form SC 13D/A filed by Paratek Pharmaceuticals Inc. (Amendment)

SEC Form SC 13D filed by Paratek Pharmaceuticals Inc.

$PRTK FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for NUZYRA issued to PARATEK PHARMS INC

FDA Approval for NUZYRA issued to PARATEK PHARMS INC

FDA Approval for NUZYRA

$PRTK Market Insights

Live Market Insights